Electroconvulsive Therapy, Manufacturers' Liability, and Learned Intermediaries

被引:0
作者
Appelbaum, Paul S. [1 ]
机构
[1] Columbia Univ, Dept Psychiat, New York, NY 10027 USA
关键词
D O I
10.1176/appi.ps.20240518
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Manufacturers of drugs or devices that are prescribed by physicians are protected by the "learned intermediary rule" from having to disclose risks directly to patients. Instead, they must inform physicians of these risks. But when a company fails to disclose a known risk, how can a patient gain compensation for any resulting harm? The California Supreme Court considered this question in a case involving alleged memory impairment from electroconvulsive therapy. By broadening the ways by which plaintiffs can demonstrate that the absence of a warning caused their injury, the court made it easier for patients to recover compensation for the consequences.
引用
收藏
页码:102 / 104
页数:3
相关论文
共 11 条
  • [1] [Anonymous], 2024, Plaintiffs' Opening Brief on the Merits: Himes v Somatics, LLC. No S273887 (Cal July 15, 2022)
  • [2] [Anonymous], 2024, Himes v Somatics, LLC. 549P.3d916
  • [3] [Anonymous], 1972, Cobbs v. Grant
  • [4] [Anonymous], 2022, Himes v Somatics, LLC. 29F.4th1125
  • [5] [Anonymous], 2021, Riera v Mecta Corp. CD Cal, 2:17-cv-06686-RGK-JC
  • [6] Institute of Medicine, 2010, PUBL HLTH EFF FDA 51
  • [7] The learned intermediary doctrine and patient package inserts: A balanced approach to preventing drug-related injury
    Paytash, CA
    [J]. STANFORD LAW REVIEW, 1999, 51 (05) : 1343 - 1371
  • [8] US Food and Drug Administration, 2008, Electroconvulsive Therapy De- vice. 21CFR882.5940.
  • [9] US Food and Drug Administration, 2018, Neurological Devices
  • [10] Reclassification of Electroconvulsive Therapy Devices